Literature DB >> 25845655

The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.

Sofia A Karlsson1, Ingela Jacobsson, Marit Danell Boman, Katja M Hakkarainen, Henrik Lövborg, Staffan Hägg, Anna K Jönsson.   

Abstract

PURPOSE: In March 2007, a legislative amendment was issued in Sweden compelling nurses to report all suspected adverse drug reactions (ADRs) to the national pharmacovigilance system. The aims of this study were to describe the status of ADR reporting, before and after the implementation of the legislative changes, and to describe the general characteristics of suspected ADRs reported by nurses.
METHODS: The Swedish pharmacovigilance system during the study period constituted six regional centres responsible for the handling of all spontaneous ADR reports within their region. In this study, we identified all individual ADR reports from 2005 and 2010, analysed in depth the ADR reports from two regional centres and collated information about the reporter and the nature of the reported ADR.
RESULTS: From the two regional centres, a total of 898 and 1074 reports were submitted in 2005 and 2010 respectively. Nurses submitted 31% (275 reports) of the reports in 2005 and 24% (260 reports) in 2010. Nurses' reporting of serious ADRs was 3% (seven reports) in 2005 and 7% (17 reports) in 2010 with reporting of unlabelled ADRs at 4% (11 reports) in 2005 and 17% (45 reports) in 2010. Most of the serious and/or unlabelled reactions were related to vaccine administration (14 reports in 2005 and 36 reports in 2010).
CONCLUSIONS: The overall ADR reporting by nurses did not appear to increase after the change in reporting legislation. The proportion of serious and/or unlabelled ADRs reported by nurses did however appear to increase during the same period. Taken together, our data suggests that further pro-active measures should be considered in order to involve nurses in the reporting of suspected ADRs.

Mesh:

Year:  2015        PMID: 25845655     DOI: 10.1007/s00228-015-1839-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Specialist nurse reporting of adverse drug reactions.

Authors:  S Morrison-Griffiths; M Pirmohamed
Journal:  Prof Nurse       Date:  2000-02

2.  Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization.

Authors:  Mia von Euler; Erik Eliasson; Gunnar Ohlén; Ulf Bergman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-03       Impact factor: 2.890

3.  Nurses are increasingly involved in pharmacovigilance in Sweden.

Authors:  Johanna Ulfvarson; Stefan Mejyr; Ulf Bergman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-05       Impact factor: 2.890

4.  Adverse drug reaction reporting by nurses in Sweden.

Authors:  M Bäckström; Elisabet Ekman; T Mjörndal
Journal:  Eur J Clin Pharmacol       Date:  2007-04-03       Impact factor: 2.953

5.  Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden.

Authors:  Elisabet Ekman; M Bäckström
Journal:  Eur J Clin Pharmacol       Date:  2008-09-30       Impact factor: 2.953

6.  Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports.

Authors:  Diogo Mendes; Carlos Alves; Francisco Batel Marques
Journal:  J Nurs Manag       Date:  2012-11-02       Impact factor: 3.325

Review 7.  Drug related hospital admissions in subspecialities of internal medicine.

Authors:  J Hallas
Journal:  Dan Med Bull       Date:  1996-04

Review 8.  Under-reporting of adverse drug reactions : a systematic review.

Authors:  Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

9.  Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data.

Authors:  Jürgen Stausberg; Joerg Hasford
Journal:  BMC Health Serv Res       Date:  2011-05-29       Impact factor: 2.655

10.  Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults.

Authors:  Katja M Hakkarainen; Hanna Gyllensten; Anna K Jönsson; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

View more
  6 in total

Review 1.  The key role of clinical and community health nurses in pharmacovigilance.

Authors:  Caterina Bigi; Guido Bocci
Journal:  Eur J Clin Pharmacol       Date:  2017-08-02       Impact factor: 2.953

2.  Nurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines.

Authors:  Sue Jordan; Timothy Banner; Marie Gabe-Walters; Jane M Mikhail; Jeff Round; Sherrill Snelgrove; Mel Storey; Douglas Wilson; David Hughes
Journal:  BMJ Open       Date:  2018-09-28       Impact factor: 2.692

3.  Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: A multi-centre cross sectional study.

Authors:  Thamir M AlShammari; Mohammed J Almoslem
Journal:  Saudi Pharm J       Date:  2018-04-26       Impact factor: 4.330

Review 4.  A Systematic Review of the Legal Considerations Surrounding Medicines Management.

Authors:  Mojtaba Vaismoradi; Sue Jordan; Patricia A Logan; Sara Amaniyan; Manela Glarcher
Journal:  Medicina (Kaunas)       Date:  2021-01-13       Impact factor: 2.430

5.  Under-Reporting of Adverse Drug Reactions in Finland and Healthcare Professionals' Perspectives on How to Improve Reporting.

Authors:  Andreas Sandberg; Veera Salminen; Susanna Heinonen; Mia Sivén
Journal:  Healthcare (Basel)       Date:  2022-05-31

6.  Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented.

Authors:  Laila Carolina Abu Esba; Ghada Al Mardawi; Mohammed I AlJasser; Badr Aljohani; Amjed Abu Alburak
Journal:  J Clin Pharm Ther       Date:  2020-12-07       Impact factor: 2.512

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.